scholarly journals Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

2016 ◽  
Vol Volume 8 ◽  
pp. 95-104 ◽  
Author(s):  
Winette van der Graaf ◽  
Ingrid Desar ◽  
Anastasia Constantinidou ◽  
Suzanne Kaal ◽  
Robin Jones
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Critical Appraisal ◽  
Treatment Options ◽  
Advanced Soft Tissue Sarcoma

Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma

2017 ◽  
Vol 51 (12) ◽  
pp. 1090-1098 ◽  
Author(s):  
Benjamin J. Andrick ◽  
Arpita Gandhi
Keyword(s):  
Growth Factor ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Literature Search ◽  
Data Extraction ◽  
Treatment Options ◽  
Growth Factor Receptor ◽  
Soft Tissue Sarcomas ◽  
Progression Free Survival ◽  
Advanced Soft Tissue Sarcoma

Objective: To review and summarize data on olaratumab, which was approved by the US Food and Drug Administration (FDA) in October 2016, in combination with doxorubicin, for the treatment of advanced soft tissue sarcoma. Data Sources: A literature search using PubMed was conducted using the search terms olaratumab, IMC-3G3, and advanced soft tissue sarcoma from January 2005 to June 2017. Study Selection and Data Extraction: The literature search was confined to human studies published in English. Trials of olaratumab for advanced soft tissue sarcomas were prioritized. Data Synthesis: Olaratumab is a human antiplatelet-derived growth factor receptor α monoclonal antibody. Its accelerated FDA approval was based on a phase II randomized trial of olaratumab plus doxorubicin (n = 66) versus doxorubicin monotherapy (n = 67) in patients with advanced soft tissue sarcoma. Olaratumab 15 mg/kg was administered intravenously (IV) on days 1 and 8 in combination with doxorubicin 75 mg/m2 IV on day 1 every 21 days for a total of 8 cycles compared to doxorubicin 75 mg/m2 IV monotherapy. The response rate was 18.2% with combination therapy versus 11.9% with monotherapy and median progression-free survival of 6.6 and 4.1 months, respectively. Additionally, overall survival was increased by 11.8 months in the olaratumab arm (26.5 months vs 14.7 months). Clinically relevant adverse effects in the olaratumab + doxorubicin arm included neutropenia (58%), mucositis (53%), nausea (73%), vomiting (45%), and diarrhea (34%). Conclusion: Olaratumab, in combination with doxorubicin, represents a novel treatment strategy for advanced soft tissue sarcoma and provides a significant survival advantage for this rare disease state with limited treatment options.

scholarly journals A DNA damage repair gene‐associated signature predicts responses of patients with advanced soft‐tissue sarcoma to treatment with trabectedin

2021 ◽  
Author(s):  
David S. Moura ◽  
Maria Peña‐Chilet ◽  
Juan Antonio Cordero Varela ◽  
Ramiro Alvarez‐Alegret ◽  
Carolina Agra‐Pujol ◽  
...  
Keyword(s):  
Dna Damage ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Dna Damage Repair ◽  
Advanced Soft Tissue Sarcoma ◽  
Repair Gene ◽  
Damage Repair
Sign in / Sign up

Export Citation Format

Share Document